Q-omics provides the consensus-scored SHISA5P2 profile across patient tissues and cancer cell-line models. SHISA5P2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SHISA5P2 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, SHISA5P2 RNA expression shows 13,265 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, COAD, and GBM as cancer lineages where SHISA5P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHISA5P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHISA5P2 survival associations across molecular data types. SHISA5P2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHISA5P2 RNA expression–survival associations across cancer types. High SHISA5P2 expression shows unfavorable associations in CESC, UVM, LUSC and KIRC, but favorable associations in BLCA and LAML. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for SHISA5P2 RNA expression.
This table summarizes SHISA5P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SHISA5P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHISA5P2 shows lower tumor expression in LUSC and higher tumor expression in COAD, KIRC, UCEC and BRCA. The COAD box plot shows higher SHISA5P2 RNA expression in tumor versus normal tissue (log2 FC = +0.256, t-test p < 0.001).
This table shows molecular features associated with SHISA5P2 in patient tissues and cancer cell lines. In patient samples, SHISA5P2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
